Cargando…

Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?

Detalles Bibliográficos
Autores principales:	Grinda, T., Pistilli, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539925/ https://www.ncbi.nlm.nih.gov/pubmed/37769401 http://dx.doi.org/10.1016/j.esmoop.2023.101832

Ejemplares similares

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
por: Grinda, Thomas, et al.
Publicado: (2023)

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
por: Grinda, Thomas, et al.
Publicado: (2023)

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Prepare or perish - Readiness is the key to reopen for routine eye care
por: Honavar, Santosh G
Publicado: (2020)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Intracranial hypotension in a breast cancer patient treated with epidural blood patches
por: Minot-This, Marie-Sophie, et al.
Publicado: (2023)

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
por: Torres-Jiménez, Javier, et al.
Publicado: (2022)

Treatment of ErbB2 breast cancer by mitochondrial targeting
por: Eldad, Sophia, et al.
Publicado: (2020)

Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: A case report
por: Inagaki, Chiaki, et al.
Publicado: (2019)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models
por: Issa, Amine, et al.
Publicado: (2013)

A reason why the ERBB2 gene is amplified and not mutated in breast cancer
por: Birnbaum, Daniel, et al.
Publicado: (2009)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
por: Zoi, Ilianna, et al.
Publicado: (2019)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen.
por: Allan, S. M., et al.
Publicado: (1993)

The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
por: Bao, Kelvin K. H., et al.
Publicado: (2021)

Targeting ERBB2 mutations in solid tumors: biological and clinical implications
por: Cousin, Sophie, et al.
Publicado: (2018)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs
por: Henjes, F, et al.
Publicado: (2012)

Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies
por: Wang, Nannan, et al.
Publicado: (2022)

Routine Bone Imaging for Metastatic Renal Cell Carcinoma: Is it Time?
por: Parikh, Mamta
Publicado: (2021)

Genome profiling of ERBB2-amplified breast cancers
por: Sircoulomb, Fabrice, et al.
Publicado: (2010)

Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy
por: Mouabbi, Jason A., et al.
Publicado: (2023)

Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?
por: Tripathy, Debu, et al.
Publicado: (2014)

Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer
por: Gautam, Shailendra K., et al.
Publicado: (2020)

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer
por: Foster, Fiona M, et al.
Publicado: (2009)

Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research
por: Cardillo, Anthony B., et al.
Publicado: (2023)

Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use?
por: Bestard, Oriol, et al.
Publicado: (2023)

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
por: Pandya, K, et al.
Publicado: (2011)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2
por: Dong, H, et al.
Publicado: (2017)

The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2(+) breast cancer cells
por: D'Alesio, Carolina, et al.
Publicado: (2019)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study
por: Dai, Xuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_di42apej51jlmgercg7l3uu4pc